$154 M

CALA Mkt cap, 22-Jul-2021
Calithera Biosciences Net income (Q1, 2021)-20.4 M
Calithera Biosciences EBIT (Q1, 2021)-20.8 M
Calithera Biosciences Cash, 31-Mar-2021101.4 M
Calithera Biosciences EV55.4 M
Get notified regarding key financial metrics and revenue changes at Calithera BiosciencesLearn more
Banner background

Calithera Biosciences Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.0m22.3m

R&D expense

16.4m23.7m27.7m43.1m66.2m76.3m71.0m

General and administrative expense

5.4m9.1m10.6m12.5m13.3m16.6m20.4m

Operating expense total

21.7m32.8m38.3m55.6m79.5m92.9m91.4m

EBIT

(21.7m)(32.8m)(38.3m)(29.7m)(57.3m)(92.9m)(91.4m)

EBIT margin, %

(114%)(257%)

Interest expense

175.0k330.0k1.9m2.7m

Interest income

3.0m1.3m

Pre tax profit

(27.8m)(54.6m)(89.9m)(90.1m)

Net Income

(21.7m)(32.6m)(38.0m)(27.8m)(54.6m)(89.9m)(90.1m)

Calithera Biosciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.0m6.1m10.6m48.5m51.1m60.4m107.1m

Accounts Receivable

1.1m2.0m482.0k1.5m

Prepaid Expenses

2.7m2.1m2.0m2.0m

Inventories

1.9m2.6m1.8m

Current Assets

103.9m72.5m53.6m167.7m140.3m159.8m118.7m

PP&E

861.0k931.0k899.0k1.8m1.5m992.0k690.0k

Total Assets

104.8m75.8m54.8m192.5m142.7m168.8m125.6m

Accounts Payable

693.0k562.0k398.0k1.1m1.2m2.1m2.0m

Current Liabilities

4.1m3.8m4.5m39.0m14.9m19.6m18.4m

Long-term debt

6.7m11.5m

Total Debt

6.7m11.5m

Total Liabilities

4.9m42.1m16.0m26.3m23.2m

Common Stock

4.0k4.0k6.0k7.0k

Additional Paid-in Capital

152.2m156.4m172.4m300.9m323.0m428.5m478.6m

Retained Earnings

(51.9m)(84.5m)(122.5m)(150.3m)(196.2m)(286.1m)(376.2m)

Total Equity

100.4m71.8m49.9m150.3m126.7m142.4m102.4m

Financial Leverage

1 x1.1 x1.1 x1.3 x1.1 x1.2 x1.2 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

34.9m73.9m11.3m8.4m12.2m7.3m11.6m89.1m58.0m39.4m54.8m55.9m61.1m40.6m76.8m21.7m40.5m114.9m120.6m101.4m

Accounts Receivable

13.6m2.3m2.2m1.8m2.5m1.8m2.5m1.7m1.7m976.0k923.0k466.0k1.0m

Prepaid Expenses

1.4m1.7m1.7m1.8m2.3m1.9m1.6m1.8m1.9m4.3m3.0m1.5m1.6m1.7m1.5m1.5m1.8m1.5m1.8m2.6m

Current Assets

36.3m90.3m79.4m83.7m68.5m62.3m57.9m170.7m170.4m172.1m155.8m145.4m144.8m121.2m156.5m136.8m137.9m156.6m140.0m106.5m

PP&E

785.0k824.0k816.0k801.0k875.0k854.0k915.0k913.0k977.0k1.4m1.7m1.6m1.6m1.3m1.2m1.1m900.0k808.0k744.0k617.0k

Total Assets

39.6m96.9m90.7m84.5m71.6m63.2m58.9m223.9m214.1m205.5m178.6m159.0m147.7m131.9m166.4m146.3m149.7m164.9m147.7m110.7m

Accounts Payable

879.0k559.0k923.0k565.0k1.1m1.4m1.3m600.0k410.0k1.3m2.2m1.1m517.0k1.6m1.3m713.0k739.0k672.0k2.6m1.6m

Current Liabilities

4.1m3.5m4.2m5.8m4.0m4.7m4.7m33.8m34.4m37.4m29.6m10.6m10.6m17.9m19.4m18.5m15.8m15.9m19.8m13.8m

Long-term debt

8.0m7.6m7.2m6.3m5.8m5.3m2.7m

Non-Current Liabilities

292.0k

Total Debt

8.0m7.6m7.2m6.3m5.8m5.3m2.7m

Total Liabilities

4.4m3.8m4.4m5.9m4.3m5.0m5.1m58.2m51.6m47.5m30.7m11.8m11.8m25.9m27.0m25.7m22.0m21.6m25.1m16.5m

Common Stock

338.0k2.0k2.0k2.0k2.0k2.0k2.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k5.0k5.0k6.0k7.0k7.0k7.0k

Additional Paid-in Capital

10.0m152.8m153.9m155.0m161.3m162.6m167.0m293.9m295.9m297.6m302.9m305.2m312.8m325.9m383.4m385.0m438.1m474.1m476.2m490.8m

Retained Earnings

(45.0m)(59.7m)(67.5m)(76.4m)(94.1m)(104.4m)(113.0m)(128.1m)(133.3m)(139.4m)(154.7m)(157.8m)(176.7m)(219.9m)(244.1m)(264.4m)(310.5m)(330.9m)(353.7m)(396.6m)

Total Equity

(35.0m)93.1m86.3m78.6m67.3m58.2m53.8m165.7m162.5m158.1m147.9m147.2m135.9m106.0m139.4m120.7m127.7m143.3m122.6m94.2m

Financial Leverage

-1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.4 x1.3 x1.3 x1.2 x1.1 x1.1 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x

Calithera Biosciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(21.7m)(32.6m)(38.0m)(27.8m)(54.6m)(89.9m)(90.1m)

Depreciation and Amortization

361.0k404.0k297.0k365.0k505.0k479.0k364.0k

Accounts Receivable

(1.1m)(855.0k)1.5m(1.1m)

Inventories

(1.5m)(673.0k)787.0k

Accounts Payable

543.0k(131.0k)(28.0k)674.0k175.0k816.0k(58.0k)

Cash From Operating Activities

(19.2m)(29.9m)(31.0m)13.8m(64.8m)(78.7m)(84.3m)

Purchases of PP&E

(556.0k)(441.0k)(401.0k)(1.2m)(214.0k)(7.0k)(61.0k)

Cash From Investing Activities

(486.0k)(66.8m)23.7m(98.8m)52.8m(10.8m)89.0m

Cash From Financing Activities

87.9m845.0k11.8m122.9m14.6m98.9m42.1m

Net Change in Cash

37.9m2.6m9.4m46.7m

Calithera Biosciences Ratios

USDQ3, 2014

Financial Leverage

-1.1 x

Calithera Biosciences Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase I/II Trials Products

1